Tarhini AA - Search Results

1

Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique.

Mansfield C, Myers K, Klein K, Patel J, Nakasato A, Ling YL, Tarhini AA. Mansfield C, et al. Among authors: tarhini aa. Future Oncol. 2021 Jun;17(17):2151-2167. doi: 10.2217/fon-2020-1193. Epub 2021 Mar 12. Future Oncol. 2021. PMID: 33709791 Free article.

2

Oblimersen in the treatment of metastatic melanoma.

Tarhini AA, Kirkwood JM. Tarhini AA, et al. Future Oncol. 2007 Jun;3(3):263-71. doi: 10.2217/14796694.3.3.263. Future Oncol. 2007. PMID: 17547520 Review.

3

Adjuvant Therapy for Melanoma.

Agha A, Tarhini AA. Agha A, et al. Among authors: tarhini aa. Curr Oncol Rep. 2017 May;19(5):36. doi: 10.1007/s11912-017-0594-5. Curr Oncol Rep. 2017. PMID: 28417343 Review.

4

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K. Tawbi HA, et al. N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453. N Engl J Med. 2018. PMID: 30134131 Free PMC article. Clinical Trial.

5

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.

Tarhini A, Ghate SR, Ionescu-Ittu R, Manceur AM, Ndife B, Jacques P, Laliberté F, Nakasato A, Burne R, Duh MS. Tarhini A, et al. Melanoma Res. 2018 Dec;28(6):618-628. doi: 10.1097/CMR.0000000000000507. Melanoma Res. 2018. PMID: 30216199 Free PMC article.

6

Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study.

Tarhini A, Ghate S, Ionescu-Ittu R, Shi S, Nakasato A, Ndife B, Laliberté F, Burne R, Duh MS. Tarhini A, et al. Future Oncol. 2019 Feb;15(4):359-370. doi: 10.2217/fon-2018-0671. Epub 2018 Oct 15. Future Oncol. 2019. PMID: 30317881

7

Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma.

Sharma R, Koruth R, Kanters S, Druyts E, Tarhini A. Sharma R, et al. J Comp Eff Res. 2019 Dec;8(16):1349-1363. doi: 10.2217/cer-2019-0061. Epub 2019 Nov 28. J Comp Eff Res. 2019. PMID: 31778073 Free article.

8

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Tarhini AA, et al. J Clin Oncol. 2020 Feb 20;38(6):567-575. doi: 10.1200/JCO.19.01381. Epub 2019 Dec 27. J Clin Oncol. 2020. PMID: 31880964 Free PMC article. Clinical Trial.

9

The current state of adjuvant therapy of melanoma.

Tarhini AA. Tarhini AA. Lancet Oncol. 2020 Nov;21(11):1394-1395. doi: 10.1016/S1470-2045(20)30544-1. Epub 2020 Sep 19. Lancet Oncol. 2020. PMID: 32961120 No abstract available.

10

Adjuvant Therapy of Melanoma.

Tarhini AA. Tarhini AA. Hematol Oncol Clin North Am. 2021 Feb;35(1):73-84. doi: 10.1016/j.hoc.2020.08.012. Epub 2020 Oct 26. Hematol Oncol Clin North Am. 2021. PMID: 33759774 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

198 results

Search Page